Pre-surgical Evaluation of Denosumab in Patients With Operable Invasive Breast Cancer

Brief description of study

The goal of this Phase 0 (biomarker) study is to evaluate tumor-specific biomarkers of RANK/RANKL expression in early breast cancer. It will also provide insight into changes in the tumor microenvironment induced by the RANKL inhibitor, denosumab, which may decrease the ability of tumor to spread.


Clinical Study Identifier: s14-01311
ClinicalTrials.gov Identifier: NCT02900469
Principal Investigator: Sylvia Adams
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.